Want to see KR:950210 full AI Analyst Report?
Top Page
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
(950210)
Select Model
Select Model
Rating:45Neutral
Price Target:
₩4,924.00
Action:N/A
Date:10/28/26
The score is held down primarily by weak and volatile financial performance (large 2026 losses, negative gross profit) and persistent cash burn, despite strong revenue growth and a moderately leveraged balance sheet. Technicals are also unfavorable with a pronounced downtrend and bearish momentum. Valuation contributes limited support because the company is loss-making (negative P/E) and dividend yield is unavailable.
Positive Factors
Rapid Revenue Growth
Rapid revenue expansion indicates that Prestige BioPharma is increasing commercial scale across its biologics activities. If supported by approvals and partner commercialization, this growing base can improve operating leverage and provide a stronger platform for future earnings.
Negative Factors
Persistent Cash Burn
Persistent negative operating and free cash flow means the business is not yet funding operations internally. Continued reliance on external capital can increase financing risk, constrain strategic flexibility, and make execution more vulnerable if funding conditions become less favorable.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Rapid revenue expansion indicates that Prestige BioPharma is increasing commercial scale across its biologics activities. If supported by approvals and partner commercialization, this growing base can improve operating leverage and provide a stronger platform for future earnings.
Read all positive factors
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩253.61B
Dividend YieldN/A
Average Volume (3M)27.09K
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue Growth84.72%
EPS Growth-480.97%
CountryKR
Employees64
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1541.66
Shares Outstanding60,096,153
10 Day Avg. Volume35,136
30 Day Avg. Volume27,089
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)14.89
P/FCF Ratio-6.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Business Overview & Revenue Model
Company Description
Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, ...
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Jun 2025 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.06B | 14.31B | 689.08M | 161.84M | 0.00 |
| Gross Profit | -16.36B | -24.01B | -528.79M | 127.90M | -3.87B |
| EBITDA | -60.84B | 33.31B | -31.06B | 10.50B | -206.91B |
| Net Income | -91.47B | 22.27B | -32.92B | 17.57B | -211.45B |
Balance Sheet | |||||
| Total Assets | 741.41B | 741.92B | 711.72B | 741.60B | 499.81B |
| Cash, Cash Equivalents and Short-Term Investments | 63.01B | 173.71B | 228.81B | 301.41B | 303.27B |
| Total Debt | 106.11B | 144.18B | 89.67B | 86.18B | 4.25B |
| Total Liabilities | 234.46B | 236.15B | 196.22B | 195.37B | 69.88B |
| Stockholders Equity | 434.21B | 408.95B | 439.09B | 450.51B | 429.94B |
Cash Flow | |||||
| Free Cash Flow | -62.48B | -95.04B | -76.02B | -125.89B | -114.02B |
| Operating Cash Flow | -56.51B | -54.34B | -48.03B | -60.27B | -45.91B |
| Investing Cash Flow | 42.70B | -99.43B | 132.46B | -148.61B | -184.69B |
| Financing Cash Flow | -50.80B | 49.81B | -1.46B | 53.18B | -4.50B |
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Technical Analysis
Negative
―
Price Trends
5999.40
Negative
6066.70
Negative
8049.10
Negative
Market Momentum
-330.35
Positive
16.11
Positive
10.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:950210, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 5564.50, equal to the 50-day MA of 5999.40, and equal to the 200-day MA of 8049.10, indicating a bearish trend. The MACD of -330.35 indicates Positive momentum. The RSI at 16.11 is Positive, neither overbought nor oversold. The STOCH value of 10.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:950210.
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₩613.71B | 13.10 | ― | 0.49% | 51.28% | 124.70% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₩253.61B | -2.70 | ― | ― | 84.72% | -480.97% | |
43 Neutral | ₩291.21B | -16.97 | ― | ― | 116.74% | -482.50% | |
43 Neutral | ₩2.52T | -30.15 | ― | ― | 23.25% | -58.35% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
4,220.00
-8,460.00
-66.72%
KR:005690
Pharmicell Co., Ltd
10,230.00
-6,961.53
-40.49%
KR:011000
GeneOne Life Science, Inc.
2,670.00
-7,680.00
-74.20%
KR:064550
Bioneer Corporation
7,070.00
-7,410.00
-51.17%
KR:199800
ToolGen Incorporated
29,800.00
-26,559.59
-47.13%
KR:302440
SK bioscience Co.,Ltd.
32,150.00
-18,750.00
-36.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.